Detalhe da pesquisa
1.
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.
J Infect Dis
; 201(1): 132-41, 2010 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19929694
2.
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
J Exp Med
; 196(5): 619-28, 2002 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12208877
3.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Clin Infect Dis
; 46(11): 1769-81, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18433307
4.
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.
AIDS Res Hum Retroviruses
; 23(1): 86-92, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17263637
5.
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
Clin Cancer Res
; 9(3): 947-54, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12631591
6.
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
AIDS Res Hum Retroviruses
; 25(1): 103-14, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19108693
7.
Memory T cells and vaccines.
Vaccine
; 21(5-6): 419-30, 2003 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12531640